7 July 2015: Sharp Clinical Services, part of UDG Healthcare plc, (LON: UDG), the leading international provider of healthcare services, has expanded its storage and packaging facilities in the UK by an additional 5,000 square feet, creating an additional 10 roles at the site. The new facility based in Crickhowell is now the fourth unit of the existing Waller House building and comprises of 150 additional pallet spaces and two assembly lines. The Company’s investment is in response to new product introductions approved by the regulatory authorities.
Sharp Clinical Services is a leading provider of specialist clinical supply chain services to both large pharmaceutical and small biotech companies in the UK and US, from drug product development, analytical and manufacturing services through to increasingly complex clinical trial supplies packaging, clinical labeling and clinical distribution services. Sharp Clinical Services has a proven track record in managing the entire clinical supply chain and has a Global Depot Network of 18 depots supporting over 25 countries.
Ian Morgan, General Manager of Sharp Clinical Services UK, commented on the expansion: “The expansion of the Crickhowell facility is a landmark moment for Sharp Clinical Services in the UK, and enables us to deliver excellent, high quality service to our existing and new customers as demand for our services increases in the UK. The first commercial test ran at the end of May and full production will begin in July.”
Frank Lis, President of Sharp Clinical Services added: “This expansion has increased our global footprint and will allow us to provide our customers with a full range of services, from formulation development and pre-clinical supplies through to product launch.”
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
2 Commerce Drive
Cranbury, NJ 08512